A V Bitokov

Republican Clinical Multidisciplinary Center of High Medical Technologies, Nalchik, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does A V Bitokov research?

Dr. Bitokov studies ischemic stroke, a condition caused by a blockage in blood flow to the brain. His main focus is on the medication Revelise, which is used to dissolve clots and restore blood flow. Through extensive research involving a large number of patients, he examines how well this treatment works in actual clinical settings, particularly among older adults and those with other health conditions. Dr. Bitokov's work aims to improve patient outcomes and reduce disabilities caused by strokes, making a significant impact on recovery post-stroke.

Key findings

  • In the International PRIMA study, 49.9% of 2,202 patients treated with Revelise experienced good outcomes at discharge.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%.
  • The study demonstrated that Revelise effectively reduces stroke-related disabilities among older patients and those with comorbidities.

Frequently asked questions

Does Dr. Bitokov study ischemic stroke?
Yes, he specializes in research related to ischemic stroke and its treatments.
What treatments has Dr. Bitokov researched?
He has extensively studied the medication Revelise for treating ischemic stroke.
Is Dr. Bitokov's work relevant to older stroke patients?
Yes, his research particularly emphasizes the effectiveness of treatments in older patients and those with other health issues.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.